Compare ARK Genomic Revolution ETF (ARKG) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Nomura Holdings Inc — how do they compare? ARK Genomic Revolution ETF trades at $40.83, while Nomura Holdings Inc trades at $9.66 (market cap $27.88B). The key difference: Nomura Holdings Inc pays a 3.35% dividend while ARK Genomic Revolution ETF pays none, and Nomura Holdings Inc is trading nearer its 52-week high, ARK Genomic Revolution ETF nearer its low. Which is the better fit depends on your goals.
| ARKG | NMR | |
|---|---|---|
Sector | Sector/Thematic | Financials |
52-Week High | $43.57 | $9.66 |
52-Week Low | $23.09 | $6.30 |
Market Cap | — | $27.88B |
Dividend Yield | — | 3.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Nomura Holdings (NMR) trades at $9.66, up 1.26% today, with a bullish technical signal from moving averages. The company reported record annual revenue of $1.66 trillion and net income of $340.74 billion for 2025, driving a net income margin of 20.49%. Recent news highlights strong wholesale revenue growth and strategic acquisitions, while analyst consensus shows a hold-heavy rating with 33% buy recommendations.
The outlook is mixed; robust profitability and expansion in core segments support upside, but consecutive earnings misses and rising debt-to-asset ratios pose risks. Investor sentiment is cautiously optimistic, with technical indicators suggesting near-term momentum but overbought conditions on shorter-term RSI readings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
